Last reviewed · How we verify
Exenatide LAR
At a glance
| Generic name | Exenatide LAR |
|---|---|
| Also known as | Bydureon |
| Sponsor | University of Guadalajara |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Long-acting Exenatide and Cognitive Decline in Dysglycemic Patients (PHASE3)
- Effect of Exenatide LAR or Dulaglutide on the Variability of 24-hour Heart Rate and Blood Pressure in Type 2 Diabetes (PHASE4)
- Efficacy of Exenatide-LAR and Dapagliflozin in Overweight/Obese, Insulin Treated Patients With Type 2 Diabetes (PHASE4)
- Continuous Glucose Monitoring (CGM) in Subjects With Type 2 Diabetes Taking Twice-Daily Exenatide or Once-Weekly Exenatide
- Effects of Exenatide Long-Acting Release on Glucose Control and Safety in Subjects With Type 2 Diabetes Mellitus(DURATION - 1) (PHASE3)
- Study Examining Exenatide Long-Acting Release in Subjects With Type 2 Diabetes (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Exenatide LAR CI brief — competitive landscape report
- Exenatide LAR updates RSS · CI watch RSS
- University of Guadalajara portfolio CI